Get the Stockscreener App
22.07
3.67%
-0.84
After Hours:
22.49
0.42
+1.90%
Nektar Therapeutics stock is traded at $22.07, with a volume of 541.84K.
It is down -3.67% in the last 24 hours and down -14.32% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$22.91
Open:
$23.02
24h Volume:
541.84K
Relative Volume:
0.21
Market Cap:
$273.82M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-15.12
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-11.72%
1M Performance:
-14.32%
6M Performance:
+2,495%
1Y Performance:
+1,488%
1-Day Range:
$21.87
$23.19
1-Week Range:
$21.87
$25.99
52-Week Range:
$0.432
$37.38
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
22.07 | 396.35M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Phase 2b Repibresib Study Falls Short of Key Goals - Dermatology Times
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata - Eastern Progress
Nektar gets FDA fast track status for alopecia areata drug - Seeking Alpha
FDA Grants Fast Track Designation to Nektar's Rezpegaldesleukin in Alopecia Areata - Dermatology Times
Nektar receives FDA fast track for alopecia areata treatment - StreetInsider
FDA Fast-Tracks Revolutionary Alopecia Drug as Nektar Targets December Data Release - Stock Titan
Nektar Therapeutics to Host Earnings Call - ACCESS Newswire
Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin - Insider Monkey
Should I hold or sell Nektar Therapeutics stock in 2025Capitalize on fast-moving stock trends - jammulinksnews.com
How does Nektar Therapeutics compare to its industry peersUnlock powerful stock screening for profits - jammulinksnews.com
What are Nektar Therapeutics company’s key revenue driversFree Investment Case Studies - jammulinksnews.com
What is Nektar Therapeutics company’s growth strategyAchieve consistent high returns with low risk - jammulinksnews.com
How many analysts rate Nektar Therapeutics as a “Buy”Capitalize on market momentum for maximum gains - jammulinksnews.com
Why Nektar Therapeutics stock attracts strong analyst attentionReturn Optimized Trade Insights - metal.it
Is Nektar Therapeutics a good long term investmentDynamic capital growth - PrintWeekIndia
What drives Nektar Therapeutics stock priceFree Daily Trading Room Entry - Autocar Professional
What analysts say about Nektar Therapeutics stockTriple-digit growth rates - Autocar Professional
Nektar Therapeutics's Options: A Look at What the Big Money is Thinking - Nasdaq
Nektar Therapeutics Stock Analysis and ForecastStrong return on investment - jammulinksnews.com
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam - MSN
Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin - MSN
Why Nektar Therapeutics Stock Dived by 3% Today - AOL.com
Nektar Therapeutics Announces Pricing of $100 Million Public Offering - 富途牛牛
B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi - Barchart.com
Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis - AJMC
5 Second-Half Biopharma Milestones To Watch - BioSpace
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial - MSN
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):